Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Abstract Background Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients treated with gemcitabine/erlotinib. This study aimed to extend knowledge on...

Full description

Bibliographic Details
Main Authors: C. Benedikt Westphalen, Tobias Kukiolka, Benjamin Garlipp, Lars Hahn, Martin Fuchs, Peter Malfertheiner, Marcel Reiser, Fabian Kütting, Volker Heinemann, Andreas Beringer, Dirk T. Waldschmidt
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cancer
Subjects:
Pancreatic ductal adenocarcinoma
Gemcitabine
Erlotinib
Overall survival
Progression-free survival
Skin rash
Online Access:http://link.springer.com/article/10.1186/s12885-020-6636-7

Internet

http://link.springer.com/article/10.1186/s12885-020-6636-7

Similar Items